Cuban drug to treat COVID-19 patients in India

On Jul 14, 2020

New Delhi: The Cuban drug Itolizumab, which is regularly used for the treatment of psoriasis and which has been shown to be effective within Cuba, has now received the approval from the Indian Regulatory Office of Medicine for the treatment of COVID-19 patients with moderate to severe acute respiratory distress.

🔊Indigenous drug Itolizumab, being used to treat severe chronic plaque psoriasis, has been repurposed for #COVID19 @CDSCO_INDIA_INF has now given Restricted Emergency Use for this @Bioconlimited drug, to treat moderate to severe #COVID-19 patients
📘https://t.co/w9U76Eb6A6 pic.twitter.com/3rZP1TCCdh
— PIB in Maharashtra 🇮🇳 (@PIBMumbai) July 11, 2020

As per the team of Indian Regulatory Office of Medicine, the use of medicine will be limited to Indian patients with severe symptoms.

The approval of this medicine has been included since July 10 in India’s protocol. Itolizumab was in regular use in India for the treatment of Psoriasis, for the use of drug each coronavirus patients must submit a written informed consent, said, official.